Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Regulus Therapeutics (RGLS)

Regulus Therapeutics (RGLS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 14,475
  • Shares Outstanding, K 20,825
  • Annual Sales, $ 70 K
  • Annual Income, $ -48,710 K
  • 60-Month Beta 1.89
  • Price/Sales 203.65
  • Price/Cash Flow N/A
  • Price/Book 3.08
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -2.77
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 11/14/19
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/19
See More
  • Average Estimate -0.29
  • Number of Estimates 2
  • High Estimate -0.27
  • Low Estimate -0.30
  • Prior Year -1.18
  • Growth Rate Est. (year over year) +75.42%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.60 +15.24%
on 10/11/19
0.86 -19.17%
on 09/23/19
-0.14 (-16.99%)
since 09/18/19
3-Month
0.50 +38.30%
on 08/06/19
1.29 -46.12%
on 07/19/19
-0.53 (-43.49%)
since 07/18/19
52-Week
0.50 +38.30%
on 08/06/19
3.14 -77.86%
on 10/23/18
-1.22 (-63.80%)
since 10/18/18

Most Recent Stories

More News
Regulus Therapeutics Presents Preclinical Data Identifying RGLS4326 as a Potential Disease-Modifying Treatment for Autosomal Dominant Polycystic Kidney Disease at OTS Annual Meeting

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced that it presented preclinical...

RGLS : 0.70 (-1.28%)
Regulus Therapeutics Announces Publication in Nature Communications Identifying RGLS4326 as a Potential Promising Treatment for ADPKD

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced that Nature Communications has...

RGLS : 0.70 (-1.28%)
Regulus Therapeutics to Present at the H.C. Wainwright Global Investment Conference

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced that Jay Hagan, President and...

RGLS : 0.70 (-1.28%)
Regulus Therapeutics to Present at the Wells Fargo Healthcare Conference

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced that Jay Hagan, President and...

WFC : 49.97 (+0.73%)
RGLS : 0.70 (-1.28%)
Regulus (RGLS) Reports Q2 Loss, Misses Revenue Estimates

Regulus (RGLS) delivered earnings and revenue surprises of 50.00% and -99.28%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

RGLS : 0.70 (-1.28%)
Regulus Therapeutics Reports Second Quarter 2019 Financial Results and Recent Updates

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today reported financial...

RGLS : 0.70 (-1.28%)
Regulus Therapeutics Appoints Cris Calsada as Chief Financial Officer

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced the appointment of Cris Calsada...

RGLS : 0.70 (-1.28%)
Regulus Therapeutics Announces RGLS4326 Program Update

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced a program update for RGLS4326...

RGLS : 0.70 (-1.28%)
Watch for Regulus Therapeu to Potentially Pullback After Gaining 7.86% Yesterday

Regulus Therapeu (NASDAQ:RGLS) traded in a range yesterday that spanned from a low of $1.51 to a high of $1.59. Yesterday, the shares gained 7.9%, which took the trading range above the 3-day high of...

RGLS : 0.70 (-1.28%)
Regulus Therapeutics Reports First Quarter 2019 Financial Results and Recent Updates

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today reported financial...

RGLS : 0.70 (-1.28%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More Share

Trade RGLS with:

Business Summary

Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs, called microRNA therapeutics. The Company's products aim to treat or prevent hepatitis C infections, cardiovascular disease, fibrosis, oncology, immuno-inflammatory diseases, and...

See More

Key Turning Points

2nd Resistance Point 0.75
1st Resistance Point 0.72
Last Price 0.70
1st Support Level 0.67
2nd Support Level 0.65

See More

52-Week High 3.14
Fibonacci 61.8% 2.13
Fibonacci 50% 1.82
Fibonacci 38.2% 1.51
Last Price 0.70
52-Week Low 0.50

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar